Stay updated on Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check3 days agoChange DetectedPage revision updated to v3.0.2 and Back to Top UI element removed.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to include a new facility name and location, as well as specific details about a clinical trial involving pembrolizumab and cabozantinib for renal cell carcinoma. Notably, previous mentions of clear cell renal cell carcinoma and various pharmacological terms have been removed.SummaryDifference3%
- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check39 days agoChange DetectedThe web page has been updated from version v2.16.10 to v2.16.11.SummaryDifference0.0%
- Check46 days agoChange DetectedThe page has been updated to version v2.16.10, and the previous service alert regarding planned maintenance has been removed.SummaryDifference0.6%
Stay in the know with updates to Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab+Cabozantinib in Metastatic Renal Cell Carcinoma Clinical Trial page.